← Back to Search

Behavioral Intervention

Exercise Rehabilitation for Peripheral Neuropathy (EX-CIPN Trial)

Phase 1
Recruiting
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The presence of peripheral neuropathy due to chemotherapy as established via clinical assessment
Independent with ambulation and transfers with or without ambulatory assistance (EGOG 0-2)
Must not have
Currently taking ado-trastuzumab emtansine (TDM1) (ex. Kadcyla)
Pre-existing neuropathy prior to the start of chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, post-intervention (10 weeks), 3-months post-intervention (20-24 weeks)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to determine if a specific exercise program called EX-CIPN is safe and effective in helping cancer survivors with persistent chemotherapy-induced peripheral neuropathy (CIPN). Participants will undergo assessments and

Who is the study for?
This trial is for cancer survivors who are dealing with persistent chemotherapy-induced peripheral neuropathy (CIPN). Participants should be willing to engage in a 10-week exercise program, receive health coaching calls, and wear a FitBit. Specific eligibility criteria were not provided.
What is being tested?
The EX-CIPN intervention being tested involves an individualized exercise program designed to treat symptoms of CIPN. The study will assess the safety, acceptability, and feasibility of this approach through participant assessments at various stages.
What are the potential side effects?
Since the intervention is exercise-based, typical side effects may include muscle soreness or strain. However, as it's tailored for individuals with CIPN, any adverse effects related to exacerbating their condition will be closely monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have nerve damage from chemotherapy.
Select...
I can walk and move around on my own, with or without help.
Select...
I was treated for cancer, including advanced gynecologic cancer, with the goal of curing it.
Select...
I experience significant numbness, tingling, or neuropathic pain.
Select...
I am not planning to undergo chemotherapy within the next 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on Kadcyla (TDM1) treatment.
Select...
I had nerve damage before starting chemotherapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, post-intervention (10 weeks), 3-months post-intervention (20-24 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, post-intervention (10 weeks), 3-months post-intervention (20-24 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Accrual Rate
Adherence
Intervention Safety
+1 more
Secondary study objectives
Aerobic Functional Capacity
Balance
CIPN Symptoms
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EX-CIPN Exercise- Based interventionExperimental Treatment1 Intervention
This arm is provided with an intervention that includes an individualized exercise program, remote monitoring, and remote person-to-person clinical support.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,519 Previous Clinical Trials
503,031 Total Patients Enrolled
1 Trials studying Peripheral Neuropathy
25 Patients Enrolled for Peripheral Neuropathy
~23 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top